{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:00:47Z","timestamp":1793325647781,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T00:00:00Z","timestamp":1693008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T00:00:00Z","timestamp":1693008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010293","name":"Seattle Genetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010293","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Enfortumab vedotin is an antibody\u2013drug conjugate (ADC) comprised of a Nectin-4\u2013directed antibody and monomethyl auristatin E (MMAE), which is primarily eliminated through P-glycoprotein (P-gp)\u2013mediated excretion and cytochrome P450 3A4 (CYP3A4)\u2013mediated metabolism. A physiologically based pharmacokinetic (PBPK) model was developed to predict effects of combined P-gp with CYP3A4 inhibitor\/inducer (ketoconazole\/rifampin) on MMAE exposure when coadministered with enfortumab vedotin and study enfortumab vedotin with CYP3A4 (midazolam) and P-gp (digoxin) substrate exposure. A PBPK model was built for enfortumab vedotin and unconjugated MMAE using the PBPK simulator ADC module. A similar model was developed with brentuximab vedotin, an ADC with the same valine-citrulline\u2013MMAE linker as enfortumab vedotin, for MMAE drug\u2013drug interaction (DDI) verification using clinical data. The DDI simulation predicted a less-than-2-fold increase in MMAE exposure with enfortumab vedotin plus ketoconazole (MMAE geometric mean ratio [GMR] for maximum concentration [C<jats:sub>max<\/jats:sub>], 1.15; GMR for area under the time-concentration curve from time 0 to last quantifiable concentration [AUC<jats:sub>last<\/jats:sub>], 1.38). Decreased MMAE exposure above 50% but below 80% was observed with enfortumab vedotin plus rifampin (MMAE GMR C<jats:sub>max<\/jats:sub>, 0.72; GMR AUC<jats:sub>last<\/jats:sub>, 0.47). No effect of enfortumab vedotin on midazolam or digoxin systemic exposure was predicted. Results suggest that combination enfortumab vedotin, P-gp, and a CYP3A4 inhibitor may result in increased MMAE exposure and patients should be monitored for potential adverse effects. Combination P-gp and a CYP3A4 inducer may result in decreased MMAE exposure. No exposure change is expected for CYP3A4 or P-gp substrates when combined with enfortumab vedotin.<\/jats:p><jats:p><jats:bold>ClinicalTrials.gov identifier<\/jats:bold> Not applicable.<\/jats:p>","DOI":"10.1007\/s10928-023-09877-5","type":"journal-article","created":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T11:01:48Z","timestamp":1693047708000},"page":"417-428","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Physiologically based pharmacokinetic model to predict drug\u2013drug interactions with the antibody\u2013drug conjugate enfortumab vedotin"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1771-3245","authenticated-orcid":false,"given":"Mary P.","family":"Choules","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiying","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bonate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,26]]},"reference":[{"issue":"32","key":"9877_CR1","doi-asserted-by":"publisher","first-page":"4343","DOI":"10.2217\/fon-2021-0573","volume":"17","author":"Z Hepp","year":"2021","unstructured":"Hepp Z, Shah SN, Liang SY, Tan K, Balakrishna S (2021) Real-world outcomes in locally advanced or metastatic urothelial carcinoma following platinum and PD-1\/L1 inhibitor therapy. Future Oncol 17(32):4343\u20134353. https:\/\/doi.org\/10.2217\/fon-2021-0573","journal-title":"Future Oncol"},{"key":"9877_CR2","unstructured":"National Cancer Institute Surveillance E, and End Results Program (2022) Cancer stat facts: bladder cancer. https:\/\/seercancer.gov\/statfacts\/html\/urinbhtml. Accessed on August 26, 2022."},{"issue":"1","key":"9877_CR3","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/s41598-018-19199-z","volume":"8","author":"MCS Wong","year":"2018","unstructured":"Wong MCS, Fung FDH, Leung C, Cheung WWL, Goggins WB, Ng CF (2018) The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. Sci Rep 8(1):1129. https:\/\/doi.org\/10.1038\/s41598-018-19199-z","journal-title":"Sci Rep"},{"key":"9877_CR4","doi-asserted-by":"publisher","first-page":"939","DOI":"10.2147\/CIA.S74322","volume":"10","author":"EA Guancial","year":"2015","unstructured":"Guancial EA, Roussel B, Bergsma DP, Bylund KC, Sahasrabudhe D, Messing E, Mohile SG, Fung C (2015) Bladder cancer in the elderly patient: challenges and solutions. Clin Interv Aging 10:939\u2013949. https:\/\/doi.org\/10.2147\/CIA.S74322","journal-title":"Clin Interv Aging"},{"issue":"7","key":"9877_CR5","doi-asserted-by":"publisher","first-page":"e580","DOI":"10.1093\/oncolo\/oyac053","volume":"27","author":"E Ramsdale","year":"2022","unstructured":"Ramsdale E, Mohamed M, Yu V, Otto E, Juba K, Awad H, Moorthi K, Plumb S, Patil A, Vogelzang N, Dib E, Mohile S (2022) Polypharmacy, potentially inappropriate medications, and drug-drug interactions in vulnerable older adults with advanced cancer initiating cancer treatment. Oncologist 27(7):e580\u2013e588. https:\/\/doi.org\/10.1093\/oncolo\/oyac053","journal-title":"Oncologist"},{"key":"9877_CR6","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3389\/fphar.2016.00358","volume":"7","author":"O Laatikainen","year":"2016","unstructured":"Laatikainen O, Sneck S, Bloigu R, Lahtinen M, Lauri T, Turpeinen M (2016) Hospitalizations due to adverse drug events in the elderly-a retrospective register study. Front Pharmacol 7:358. https:\/\/doi.org\/10.3389\/fphar.2016.00358","journal-title":"Front Pharmacol"},{"issue":"5","key":"9877_CR7","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1093\/annonc\/mdv029","volume":"26","author":"RWF van Leeuwen","year":"2015","unstructured":"van Leeuwen RWF, Jansman FGA, van den Bemt P, de Man F, Piran F, Vincenten I, Jager A, Rijneveld AW, Brugma JD, Mathijssen RHJ, van Gelder T (2015) Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions. Ann Oncol 26(5):992\u2013997. https:\/\/doi.org\/10.1093\/annonc\/mdv029","journal-title":"Ann Oncol"},{"issue":"6","key":"9877_CR8","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.amjopharm.2011.10.004","volume":"9","author":"LE Hines","year":"2011","unstructured":"Hines LE, Murphy JE (2011) Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother 9(6):364\u2013377. https:\/\/doi.org\/10.1016\/j.amjopharm.2011.10.004","journal-title":"Am J Geriatr Pharmacother"},{"issue":"6","key":"9877_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40262-020-00867-1","volume":"59","author":"M Elmeliegy","year":"2020","unstructured":"Elmeliegy M, Vourvahis M, Guo C, Wang DD (2020) Effect of p-glycoprotein (p-gp) inducers on exposure of p-gp substrates: review of clinical drug-drug interaction studies. Clin Pharmacokinet 59(6):699\u2013714. https:\/\/doi.org\/10.1007\/s40262-020-00867-1","journal-title":"Clin Pharmacokinet"},{"issue":"29","key":"9877_CR10","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/JCO.19.01140","volume":"37","author":"JE Rosenberg","year":"2019","unstructured":"Rosenberg JE, O\u2019Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, Galsky MD, Hahn NM, Gartner EM, Pinelli JM, Liang SY, Melhem-Bertrandt A, Petrylak DP (2019) Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy. J Clin Oncol 37(29):2592\u20132600. https:\/\/doi.org\/10.1200\/JCO.19.01140","journal-title":"J Clin Oncol"},{"key":"9877_CR11","unstructured":"Brentuximab Vedotin (Adcetris) (2011) Clinical Pharmacology and Biopharmaceutics Review(s). Center for Drug Evaluation and Research. 25 Feb 2011."},{"issue":"2","key":"9877_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/00365510600986084","volume":"67","author":"UL Larsen","year":"2007","unstructured":"Larsen UL, Hyldahl Olesen L, Guldborg Nyvold C, Eriksen J, Jakobsen P, Ostergaard M, Autrup H, Andersen V (2007) Human intestinal P-glycoprotein activity estimated by the model substrate digoxin. Scand J Clin Lab Invest 67(2):123\u2013134. https:\/\/doi.org\/10.1080\/00365510600986084","journal-title":"Scand J Clin Lab Invest"},{"issue":"2","key":"9877_CR13","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1172\/JCI6663","volume":"104","author":"B Greiner","year":"1999","unstructured":"Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104(2):147\u2013153. https:\/\/doi.org\/10.1172\/JCI6663","journal-title":"J Clin Invest"},{"key":"9877_CR14","unstructured":"Center for Drug Evaluation and Research (2019) Application Number: 761137Orig1s000. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/761137Orig1s000MultiDiscliplineR.pdf. Accessed February 1, 2023."},{"key":"9877_CR15","doi-asserted-by":"publisher","unstructured":"Chang HP, Cheung YK, Shah DK (2021) Whole-body pharmacokinetics and physiologically based pharmacokinetic model for monomethyl auristatin E (MMAE). J Clin Med 10(6). https:\/\/doi.org\/10.3390\/jcm10061332","DOI":"10.3390\/jcm10061332"},{"issue":"10","key":"9877_CR16","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1200\/JCO.19.02044","volume":"38","author":"J Rosenberg","year":"2020","unstructured":"Rosenberg J, Sridhar SS, Zhang J, Smith D, Ruether D, Flaig TW, Baranda J, Lang J, Plimack ER, Sangha R, Heath EI, Merchan J, Quinn DI, Srinivas S, Milowsky M, Wu C, Gartner EM, Zuo P, Melhem-Bertrandt A, Petrylak DP (2020) EV-101: a phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma. J Clin Oncol 38(10):1041\u20131049. https:\/\/doi.org\/10.1200\/JCO.19.02044","journal-title":"J Clin Oncol"},{"issue":"8","key":"9877_CR17","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/jcph.116","volume":"53","author":"TH Han","year":"2013","unstructured":"Han TH, Gopal AK, Ramchandren R, Goy A, Chen R, Matous JV, Cooper M, Grove LE, Alley SC, Lynch CM, O\u2019Connor OA (2013) CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies. J Clin Pharmacol 53(8):866\u2013877. https:\/\/doi.org\/10.1002\/jcph.116","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"9877_CR18","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1124\/dmd.115.065920","volume":"43","author":"JE Sager","year":"2015","unstructured":"Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N (2015) Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification. Drug Metab Dispos 43(11):1823\u20131837. https:\/\/doi.org\/10.1124\/dmd.115.065920","journal-title":"Drug Metab Dispos"},{"issue":"Suppl 1","key":"9877_CR19","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.1002\/jcph.1718","volume":"60","author":"D Samineni","year":"2020","unstructured":"Samineni D, Ding H, Ma F, Shi R, Lu D, Miles D, Mao J, Li C, Jin J, Wright M, Girish S, Chen Y (2020) Physiologically based pharmacokinetic model-informed drug development for polatuzumab vedotin: label for drug-drug interactions without dedicated clinical trials. J Clin Pharmacol 60(Suppl 1):S120\u2013S131. https:\/\/doi.org\/10.1002\/jcph.1718","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"9877_CR20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s40262-014-0182-x","volume":"54","author":"Y Chen","year":"2015","unstructured":"Chen Y, Samineni D, Mukadam S, Wong H, Shen BQ, Lu D, Girish S, Hop C, Jin JY, Li C (2015) Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates. Clin Pharmacokinet 54(1):81\u201393. https:\/\/doi.org\/10.1007\/s40262-014-0182-x","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"9877_CR21","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00280-021-04250-0","volume":"87","author":"SN Liu","year":"2021","unstructured":"Liu SN, Li C (2021) Clinical pharmacology strategies in supporting drug development and approval of antibody-drug conjugates in oncology. Cancer Chemother Pharmacol 87(6):743\u2013765. https:\/\/doi.org\/10.1007\/s00280-021-04250-0","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"9877_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.29245\/2578-3009\/2018\/2.1126","volume":"2","author":"JMS L\u00f3pez-Matencio","year":"2018","unstructured":"L\u00f3pez-Matencio JMS, NC, Baladr\u00f3n AM, Santos Casta\u00f1eda S (2018) Drug interactions of monoclonal antibodies-clinical perspective. J Immunol Sci 2(2):4\u20137. https:\/\/doi.org\/10.29245\/2578-3009\/2018\/2.1126","journal-title":"J Immunol Sci"},{"key":"9877_CR23","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.phrs.2016.07.015","volume":"111","author":"N Ferri","year":"2016","unstructured":"Ferri N, Bellosta S, Baldessin L, Boccia D, Racagni G, Corsini A (2016) Pharmacokinetics interactions of monoclonal antibodies. Pharmacol Res 111:592\u2013599. https:\/\/doi.org\/10.1016\/j.phrs.2016.07.015","journal-title":"Pharmacol Res"},{"issue":"9","key":"9877_CR24","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1084\/jem.20151267","volume":"212","author":"S Bournazos","year":"2015","unstructured":"Bournazos S, DiLillo DJ, Ravetch JV (2015) The role of Fc-FcgammaR interactions in IgG-mediated microbial neutralization. J Exp Med 212(9):1361\u20131369. https:\/\/doi.org\/10.1084\/jem.20151267","journal-title":"J Exp Med"},{"key":"9877_CR25","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1146\/annurev-pharmtox-010510-100510","volume":"51","author":"H Zhou","year":"2011","unstructured":"Zhou H, Mascelli MA (2011) Mechanisms of monoclonal antibody-drug interactions. Annu Rev Pharmacol Toxicol 51:359\u2013372. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010510-100510","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"9877_CR26","unstructured":"Brentuximab Vedotin (Adcetris). Pharmacology Review(s). 125388Orig1s000. Center for Drug Evaluation and Research. 25 Feb 2011. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/125388Orig1s000Approv.pdf"},{"key":"9877_CR27","doi-asserted-by":"publisher","unstructured":"Hedrich WD, Fandy TE, Ashour HM, Wang H, Hassan HE (2018) Antibody-drug conjugates: pharmacokinetic\/pharmacodynamic modeling, preclinical characterization, clinical studies, and lessons learned. Clin Pharmacokinet 57(6):687\u2013703. https:\/\/doi.org\/10.1007\/s40262-017-0619-0","DOI":"10.1007\/s40262-017-0619-0"},{"key":"9877_CR28","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (2020) The Use of Physiologically Based Pharmacokinetic Analyses \u2014 Biopharmaceutics Applications for Oral Drug Product Development, Manufacturing Changes, and Controls: Guidance for Industry, Draft Guidance. https:\/\/www.fda.gov\/media\/142500\/download. Accessed February 1, 2023."},{"key":"9877_CR29","unstructured":"Hsu Y, Carroll J, Ramsay J, McDermott L (2021) Correlation of Discreet Drug-linker Variation on Antibody Drug Conjugates (ADC) to Binding Activity Using Surface Plasmon Resonance. https:\/\/www.sigmaaldrich.com\/deepweb\/assets\/sigmaaldrich\/marketing\/global\/documents\/769\/863\/adc-poster-ps7609en-ms.pdf. Accessed February 1, 2023."},{"issue":"3","key":"9877_CR30","doi-asserted-by":"publisher","first-page":"362","DOI":"10.4161\/mabs.19449","volume":"4","author":"M Acchione","year":"2012","unstructured":"Acchione M, Kwon H, Jochheim CM, Atkins WM (2012) Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates. MAbs 4(3):362\u2013372. https:\/\/doi.org\/10.4161\/mabs.19449","journal-title":"MAbs"},{"issue":"4","key":"9877_CR31","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1021\/acs.molpharmaceut.6b00082","volume":"13","author":"G Brachet","year":"2016","unstructured":"Brachet G, Respaud R, Arnoult C, Henriquet C, Dhommee C, Viaud-Massuard MC, Heuze-Vourc\u2019h N, Joubert N, Pugniere M, Gouilleux-Gruart V (2016) Increment in drug loading on an antibody-drug conjugate increases its binding to the human neonatal Fc receptor in vitro. Mol Pharm 13(4):1405\u20131412. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6b00082","journal-title":"Mol Pharm"},{"issue":"5","key":"9877_CR32","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1309\/AJCPGXK0FR4MHIHB","volume":"134","author":"MS Derycke","year":"2010","unstructured":"Derycke MS, Pambuccian SE, Gilks CB, Kalloger SE, Ghidouche A, Lopez M, Bliss RL, Geller MA, Argenta PA, Harrington KM, Skubitz AP (2010) Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker. Am J Clin Pathol 134(5):835\u2013845. https:\/\/doi.org\/10.1309\/AJCPGXK0FR4MHIHB","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"9877_CR33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13046-015-0144-7","volume":"34","author":"S Nishiwada","year":"2015","unstructured":"Nishiwada S, Sho M, Yasuda S, Shimada K, Yamato I, Akahori T, Kinoshita S, Nagai M, Konishi N, Nakajima Y (2015) Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer. J Exp Clin Cancer Res 34(1):30. https:\/\/doi.org\/10.1186\/s13046-015-0144-7","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"9877_CR34","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","volume":"76","author":"PM Challita-Eid","year":"2016","unstructured":"Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, Raitano A, Nadell R, Liu W, Lortie DR, Capo L, Verlinsky A, Leavitt M, Malik F, Avina H, Guevara CI, Dinh N, Karki S, Anand BS, Pereira DS, Joseph IB, Donate F, Morrison K, Stover DR (2016) Enfortumab vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res 76(10):3003\u20133013. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1313","journal-title":"Cancer Res"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-023-09877-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-023-09877-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-023-09877-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T21:23:03Z","timestamp":1732051383000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-023-09877-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,26]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["9877"],"URL":"https:\/\/doi.org\/10.1007\/s10928-023-09877-5","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,26]]},"assertion":[{"value":"11 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mary P. Choules is an employee of Astellas Pharma, Inc. Peiying Zuo was an employee of Astellas at the time of the analysis; any meeting attendance to support this analysis was paid for by Astellas. They report an unpaid role as Secretary and steering committee member of Mathematical and Computational Sciences (MCS) special interest group in International Society of Pharmacometrics (ISoP). Yukio Otsuka is an employee of Astellas Pharma, Inc. and reports stock or stock options with Astellas Pharma, Inc. Amit Garg is an employee of Seagen, Inc. Mei Tang is an employee of Astellas Pharma, Inc. Peter Bonate is an employee of Astellas Pharma, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This PBPK DDI study utilized data from clinical trials conducted in accordance with the Declaration of Helsinki and International Council for Harmonisation guidelines for good clinical practice.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"This PBPK DDI study utilized data from clinical trials in which written\/signed informed consent was obtained from patients before screening.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}